Drugs for diabetes are given chronically on a regular basis (in many patients for life). Moreover, a diabetes therapy must be biologically active whenever a patient eats; hence, from a practical standpoint, a diabetes drug must produce no serious side effects which can’t be controlled by other meds.
In contrast, Squalamine has a systemic half-life of only four hours, and it needs to be administered only a limited number of times during a course of therapy.
This is a valid point. I would like to look at the pIII size of drugs that have systemic action, but are administered for a localized condition. I am having trouble thinking of any. Do you have any leads?
Aside from that point, how much do you think that the PIII would run?
Bob
Market Data 
Markets 
AI
